lupus erythematosus lupus - HEALTHIES
The systemic lupus erythematosus (SLE) market continues to evolve toward biologic-driven care, with increasing treatment complexity, intensifying competition among advanced therapies, and a robust ... Yahoo Finance: Saphnelo® subcutaneous approved in Canada for the treatment of systemic lupus erythematosus Saphnelo® subcutaneous approved in Canada for the treatment of systemic lupus erythematosus A study identified an accurate approach to measuring disease activity in patients with systemic lupus erythematosus (SLE), which is crucial for clinical management. Leading Beeline Medicines’ pipeline is afimetoran, which is in Phase 2 development for systemic lupus erythematosus with data expected later this year.
Understanding the Context
Lupus Foundation of America: New Study Finds Potential Biomarker Linking Fat Imbalance to Systemic Lupus Erythematosus New Study Finds Potential Biomarker Linking Fat Imbalance to Systemic Lupus Erythematosus Clinical Advisor: Cardiovascular Risk in SLE Mostly Attributed to Lupus Nephritis, Antiphospholipid Antibodies